Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK2 as a molecular marker in myeloproliferative diseases.

Cardiovascular & hematological agents in medicinal chemistry - 1 Jul 2007

Mata R, Subirá D, García-Raso A, Llamas P

Abstract excerpt

The molecular pathogenesis of the myeloproliferative disorders (MPD) is poorly understood, except for chronic myeloid leukemia (CML). Recently, several groups have discovered a novel recurrent unique acquired clonal mutation in a tyrosine-kinase JAK2 in patients with Philadelphia-negative MPD and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to JAK2 gene
Share to Janus Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Myeloproliferative Disorders

Share to Prognosis

Source

Identifiers

PMID: 17630945
DOI: 10.2174/187152507781058654

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17630945-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2 as a molecular marker in myeloproliferative diseases.PMID 17630945Read ↗

[New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].Semantic proximity Read ↗

Clinical applications of molecular haematology: JAK2 in myeloproliferative disorders.Semantic proximity Read ↗

The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis.Semantic proximity Read ↗

Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications.Semantic proximity Read ↗

A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospectsSemantic proximity Read ↗

JAK2 Variant Signaling: Genetic, Hematologic and Immune Implication in Chronic Myeloproliferative Neoplasms.Semantic proximity Read ↗

JAK2 in myeloproliferative disorders is not just another kinase.Semantic proximity Read ↗

Jak-2 positive myeloproliferative neoplasms.Semantic proximity Read ↗

JAK2 inhibition for the treatment of hematologic and solid malignanciesSemantic proximity Read ↗

Jak2: normal function and role in hematopoietic disorders.Semantic proximity Read ↗

Clinical implications of JAK2 mutations in myeloproliferative disorders.Semantic proximity Read ↗

Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.